Literature DB >> 28941036

Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation.

Tao Zhang1, Yuan Liu1, Rong Zeng2, Qi Ling3, Peihao Wen4, Junwei Fan1, Zhihai Peng1.   

Abstract

BACKGROUNDS & AIMS: Individualized tacrolimus treatment can improve drug safety and efficacy. In this study, we aimed to investigate the association of donor and recipient small ubiquitin-like modifier 4 (SUMO4) rs237025 polymorphisms with tacrolimus elimination and the potential mechanism.
METHODS: A total of 297 liver transplant patients were enrolled in the study. CYP3A5 rs776746 and SUMO4 rs237025 were genotyped using TaqMan SNPs assays. The activity of nuclear factor-kB (NF-kB) was evaluated by luciferase assay. The expressions of CYP3A5 were detected by qRT-PCR and western blotting.
RESULTS: Tacrolimus C/D ratios was significantly lower for donor SUMO4 rs237025 AA carriers than AG/GG carriers at weeks 1, 2, 3. In multivariate analysis, donor and recipient CYP3A5 rs776747, donor SUMO4 rs237025 and total bilirubin were independent predictors of tacrolimus C/D ratios in the early post-transplantation period both in Cohort A and Cohort B. When combined donor CYP3A5 rs776746 and donor SUMO4 rs237025 genotypes, tacrolimus C/D ratios was highly significant at all investigated time points within the four groups. CYP3A5 mRNA expression in liver tissues was significantly higher for AA carriers than AG/GG patients under inflammatory stimuli after liver transplantation (LT). Furthermore, we demonstrated that SUMO4 rs237025 G allele could increase NF-κB transcriptional activity under inflammatory condition. And activation of NF-kB suppressed the expression of pregnane X receptor (PXR)-mediated CYP3A5 gene.
CONCLUSIONS: Donor SUMO4 rs237025 genetic variant was associated with higher Tac C/D ratios in the early period after LT, which might be related to the down-regulation of CYP3A5 enzyme through the NF-kB signalling pathway.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CYP3A5; liver transplantation; single-nucleotide polymorphisms; small ubiquitin-like modifier 4; tacrolimus pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28941036     DOI: 10.1111/liv.13597

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.

Authors:  Tong Lu; Xu Zhu; Shansen Xu; Mingming Zhao; Xueshi Huang; Zhanyou Wang; Limei Zhao
Journal:  Pharm Res       Date:  2019-02-04       Impact factor: 4.200

2.  The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.

Authors:  Zhaolin Chen; Xi Cheng; Liwen Zhang; Liqin Tang; Yan Fang; Hongxiao Chen; Lei Zhang; Aizong Shen
Journal:  Pharmacol Rep       Date:  2021-06-05       Impact factor: 3.024

Review 3.  Importance of genetic polymorphisms in liver transplantation outcomes.

Authors:  Tomislav Kelava; Petra Turcic; Antonio Markotic; Ana Ostojic; Dino Sisl; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

4.  The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.

Authors:  Yi Wu; Fang Fang; Zhaowen Wang; Peihao Wen; Junwei Fan
Journal:  Eur J Clin Pharmacol       Date:  2021-01-02       Impact factor: 2.953

Review 5.  Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application.

Authors:  Naoki Tanimine; Masahiro Ohira; Hiroyuki Tahara; Kentaro Ide; Yuka Tanaka; Takashi Onoe; Hideki Ohdan
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.